Skip to main content
Official Website of Stem Cell Mexico – Since 2002
Stem Cell Therapy Mexico

How safe is Stem Cell Therapy for Stroke patients?

Stem cell therapy has shown a reassuring safety profile in people who have had a stroke.

Free Consultation
Brain location on a neutral human figure

A Cochrane systematic review of randomized trials in ischemic stroke found no major safety concerns with stem cell transplantation, and the MASTERS trial, a randomized, double-blind, placebo-controlled study published in The Lancet Neurology, found that an intravenous (IV) bone-marrow-derived cell product was safe and well tolerated after acute ischemic stroke. Across many conditions, the most consistent side effect of IV mesenchymal stromal cells (MSCs) is a temporary fever, without increased rates of infection, blood clots, cancer or death in controlled trials. For stroke survivors, safety also depends on factors such as blood thinners, heart rhythm, blood pressure control, seizure risk, swallowing difficulties and fall risk. At Stem Cell Mexico, stroke protocols use only allogeneic MSCs derived from Wharton's jelly (umbilical cord tissue), usually by IV infusion, in medically stable patients, with monitoring and observation.

This guide explains what is known about safety, which stroke-related factors require attention and how risks are minimized.

What the evidence shows

Cochrane review

The Cochrane review by Boncoraglio and colleagues (2019) analyzed seven randomized trials with 401 participants with ischemic stroke who received different types of stem cells. No significant safety concerns were identified regarding mortality or adverse events.

MASTERS trial

This phase 2 trial randomized patients to an IV cell product or placebo one to two days after ischemic stroke. The cells were safe and well tolerated. Its safety findings in a vulnerable acute stroke population were reassuring.

Umbilical cord MSCs across conditions

A 2026 systematic review in Stem Cells Translational Medicine (Hum and colleagues) of 42 randomized trials with 2,280 patients receiving intravascular umbilical cord MSCs found more temporary fever, but no signals of harm for infection, thrombosis, malignancy, abnormal tissue formation or death.

What this means

Controlled studies support the safety of cell therapy in stroke, particularly with IV administration. Because stroke survivors often have cardiovascular disease and other conditions, individual screening is essential.

Safety by route

  • Intravenous infusion: minimally invasive and the route most commonly used in our protocols. Temporary fever, headache and fatigue are the most common effects.
  • Intra-arterial delivery: brings cells closer to the brain through an artery, studied in some trials, with a risk of small vessel blockage that requires specialized settings.
  • Direct surgical implantation: used in some research protocols for chronic stroke, with neurosurgical risks.

Stroke-specific safety considerations

Timing after stroke

Most patients treated at our clinic are in the subacute or chronic phase, once they are medically stable. Treatment is not performed during the acute phase outside of specialized hospital trials, and it is postponed after a recent new stroke or transient ischemic attack.

Blood thinners

Many stroke survivors take antiplatelet drugs or anticoagulants to prevent another stroke. These must never be stopped without medical guidance; stopping them can cause a new stroke. IV infusions are generally compatible with these medications.

Heart rhythm

Atrial fibrillation is a common cause of stroke. Rhythm and anticoagulation status are reviewed before treatment.

Blood pressure

High blood pressure is the most important risk factor for stroke. It should be well controlled. Fasting, travel and infusion reactions can affect blood pressure, which is monitored.

Seizures

Some people develop seizures after a stroke. Anti-seizure medications are continued on schedule, and seizures should be controlled before treatment.

Swallowing difficulties

Dysphagia increases the risk of choking and pneumonia, especially with sedation. IV infusions usually do not require sedation; medications are adapted to swallowing ability, and your companion can plan adapted meals during your stay.

Mobility and falls

Weakness, balance problems and visual field loss increase fall risk in unfamiliar places. Assistance with transfers and a companion are recommended.

Communication and cognition

Aphasia or cognitive changes may make it harder to report symptoms. Caregivers are involved in planning and monitoring.

Hemorrhagic stroke

People who had a hemorrhagic stroke require a more cautious, individual evaluation.

How we reduce risk

  • Review of brain imaging, neurology and cardiology records: stroke type, date, cause, current medications and risk factor control.
  • Stability requirement: no recent new stroke or TIA, controlled blood pressure and rhythm, controlled seizures.
  • Pre-treatment testing: complete blood count, metabolic panel, urinalysis and tumor markers.
  • A single documented cell source: Wharton's jelly MSCs from a COFEPRIS-licensed laboratory under GMP standards, with quality and safety testing before release.
  • Slow infusion with monitoring of blood pressure, heart rate, oxygen and temperature.
  • Observation with nursing supervision.
  • Accessibility and fall prevention: assistance with transfers, accessible transportation and rooms.
  • Coordination with your neurologist and rehabilitation team.

The role of caregivers

Many stroke survivors depend on a spouse, adult child or professional caregiver. Caregivers are essential partners for safety: they know the patient's baseline abilities, notice subtle changes, help with communication if speech is affected, keep medication schedules and assist with transfers. We encourage caregivers to participate in the evaluation, review the treatment plan and discharge instructions, and keep the team's contact information. Their observations before and after treatment, such as changes in walking, hand use, speech or energy, are also valuable for evaluating results objectively.

Understanding fever after an infusion in stroke survivors

Fever is the most consistently reported side effect of IV MSCs, usually mild and lasting one to two days. In stroke survivors, fever can temporarily make weakness or fatigue feel worse. It is monitored and treated promptly with paracetamol. A high or persistent fever, especially with cough or difficulty swallowing, should be evaluated, because aspiration pneumonia and urinary infections are common causes of fever after stroke and need specific treatment.

Long-term safety

Follow-up in stroke cell therapy trials has generally extended from months to a few years, without signals of increased cancer, abnormal tissue growth or serious infections. Because stroke survivors remain at risk of new cardiovascular events regardless of any treatment, continued secondary prevention, regular check-ups and prompt reporting of new symptoms are essential. Sharing your treatment records with your neurologist helps them interpret any changes in context.

Safety and benefit are separate questions

The Cochrane review found that stem cell transplantation was associated with reduced neurological impairment. Cell therapy for stroke is offered as a supportive approach alongside rehabilitation. According to the World Stroke Organization, stroke is a leading cause of death and disability worldwide, and rehabilitation and secondary prevention remain the foundation of recovery. Regenerative therapy should support, not replace, them.

Regulatory context

No stem cell product is approved by the FDA or the European Medicines Agency for stroke. In Mexico, establishments that handle stem cells operate under sanitary licenses from COFEPRIS.

Combining treatment with rehabilitation safely

Rehabilitation should continue around treatment, with a short pause on the day of the procedure and the following day. After that, most patients can resume their usual therapy program gradually, unless the medical team advises otherwise because of fatigue, fever or another reason. Let your therapists know the treatment date so they can adjust intensity during the first week and document your baseline and progress.

Who may be a safe candidate

  • Medically stable after ischemic stroke, without a recent new event.
  • Controlled blood pressure, heart rhythm, diabetes and seizures.
  • Blood thinners reviewed and continued under medical guidance.
  • Manageable swallowing and mobility needs, with a companion when required.
  • No active infection and no cancer within the past five years.

Preparing for treatment

Bring brain imaging reports, neurology and cardiology notes, and a complete medication list. Continue your blood thinners and blood pressure medications unless instructed otherwise. Share information about swallowing, mobility, communication and any seizures. Plan travel with rest and assistance.

Signs to report after treatment

Call emergency services immediately for signs of a new stroke: sudden facial drooping, arm or leg weakness, speech difficulty, sudden vision loss or severe headache. Contact the team for high or persistent fever, cough or choking with meals, chest pain, palpitations or a seizure.

What our patients usually receive

Based on the treatment plans our team prepares for patients, a typical protocol at Stem Cell Mexico includes:

  • Wharton's jelly MSCs by IV infusion, usually between 100 and 200 million cells, depending on the condition, body weight and medical review.
  • An additional intrathecal application (similar to an epidural, usually about 60 million cells) for some neurological conditions, only after the doctor reviews your medical reports and confirms you are a candidate.
  • One night at our facilities, sometimes two, with nursing and medical monitoring.
  • Consultation with your doctor and the stem cell specialist, pre-treatment laboratory tests and ground transportation from the San Diego airport area.
  • Complementary therapies, such as PRP, exosomes or NAD+, only when the doctor considers them useful; they are always listed in your written plan.

Recovery is gradual, and each person responds differently. Some patients begin noticing changes within the first weeks, while others notice them over the following months, which is why our team stays in contact after treatment to follow your progress and decide whether a second application could help.

Questions to ask during your evaluation

  • Is my condition stable enough for treatment now?
  • How will my blood thinners, blood pressure and rhythm be managed?
  • What route and dose do you recommend, and what are their risks?
  • How will swallowing and fall risks be handled?
  • How will you coordinate with my neurologist?

Bottom line

Cell therapy for stroke has a reassuring safety record in randomized trials, with temporary fever as the most common side effect of IV infusions. For stroke survivors, safety depends on medical stability, continued prevention medications and careful management of swallowing, mobility, seizures and blood pressure. A medical evaluation can help determine whether this type of regenerative treatment is appropriate and safe for your recovery, goals and medical history.

References

  1. Cochrane: Boncoraglio GB et al. Stem cell transplantation for ischemic stroke, 2019 (opens in a new tab)
  2. Hess DC et al. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Neurology, 2017 (opens in a new tab)
  3. Hum C et al. Safety of intravascular administration of umbilical-cord-derived mesenchymal stromal cells: an updated systematic review and meta-analysis. Stem Cells Translational Medicine, 2026 (opens in a new tab)
  4. World Stroke Organization (WSO): Global Stroke Fact Sheet (opens in a new tab)

Request your medical evaluation

A clearer path starts here.

Tell us a little about yourself. We’ll help you understand the next step.

Vania, patient coordinator at Stem Cell Mexico

Vania, our patient coordinator

Your questions. Your travel plans.
A real person to help.

Talk to Vania on WhatsApp (opens in a new tab)

What happens next?

  1. Your advisor contacts you.
  2. We explain the medical review.
  3. You explore your options.

Call +1 800 646 0290

Let’s begin with you.

Your inquiry starts a conversation. Treatment requires medical evaluation.

Vania · Patient Advisor

Start my free evaluation
Free Consultation